Applications of Nanotechnology in Bladder Cancer Therapy

Hsu, Jong-Wei; King, Michael R.

doi:https://doi.org/10.1260/2040-2295.3.4.535

Journal of Healthcare Engineering

On this page

Abstract References Copyright Related Articles

Research Article | Open Access

Volume 3 | Article ID 489173 | https://doi.org/10.1260/2040-2295.3.4.535

Applications of Nanotechnology in Bladder Cancer Therapy

Jong-Wei Hsu¹and Michael R. King¹

Received01 Jun 2012

Accepted01 Sept 2012

Abstract

Effective therapies can prevent superficial bladder cancer from developing into muscle-invasive stage or more severe stages which require radical cystectomy and negatively affect life quality. In terms of therapeutic approaches against superficial bladder cancer, intravesical (regional) therapy has several advantages over oral (systemic) therapy. Though urologists can directly deliver drugs to bladder lesions by intravesical instillation after transurethral resection, the efficacy of conventional drug delivery is usually low due to the bladder permeability barrier and bladder periodical discharge. Nanoparticles have been well developed as pharmaceutical carriers. By their versatile properties, nanoparticles can greatly improve the interactions between urothelium and drugs and also enhance the penetration of drugs into urothelium with lesions, which dramatically improves therapeutic efficacy. In this review, we discuss the advances of nanotechnology in bladder cancer therapy by different types of nanoparticles with different encapsulating materials.

References

R. Siegel, D. Naishadham, and A. Jemal, “Cancer statistics, 2012,” CA Cancer J Clin, vol. 62, no. 1, pp. 10–29, 2012.
View at: Google Scholar
Y. M. Hong and K. R. Loughlin, “Economic impact of tumor markers in bladder cancer surveillance,” Urology, vol. 71, no. 1, pp. 131–135, 2008.
View at: Google Scholar
J. Gee, A. L. Sabichi, and H. B. Grossman, “Chemoprevention of superficial bladder cancer,” Critical reviews in oncology/hematology, vol. 43, no. 3, pp. 277–286, 2002.
View at: Google Scholar
M. S. Cookson, H. W. Herr, Z. F. Zhang, S. Soloway, P. C. Sogani, and W. R. Fair, “The treated natural history of high risk superficial bladder cancer: 15-year outcome,” The Journal of urology, vol. 158, no. 1, pp. 62–67, 1997.
View at: Google Scholar
E. A. Schenk-Braat and C. H. Bangma, “Immunotherapy for superficial bladder cancer,” Cancer immunology, immunotherapy: CII, vol. 54, no. 5, pp. 414–423, 2005.
View at: Google Scholar
M. S. El-Bahnasawy, Y. Osman, A. El-Hefnawy et al., “Radical cystectomy and urinary diversion in women: impact on sexual function,” Scandinavian journal of urology and nephrology, vol. 45, no. 5, pp. 332–338, 2011.
View at: Google Scholar
E. A. De Bruijn, H. P. Sleeboom, P. J. van Helsdingen, A. T. van Oosterom, U. R. Tjaden, and R. A. Maes, “Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times,” International journal of cancer Journal international du cancer, vol. 51, no. 3, pp. 359–364, 1992.
View at: Google Scholar
M. Chai, M. G. Wientjes, R. A. Badalament, J. K. Burgers, and J. L. Au, “Pharmacokinetics of intravesical doxorubicin in superficial bladder cancer patients,” The Journal of urology, vol. 152, no. 2 Pt 1, pp. 374–378, 1994.
View at: Google Scholar
D. Song, M. G. Wientjes, and J. L. Au, “Bladder tissue pharmacokinetics of intravesical taxol,” Cancer chemotherapy and pharmacology, vol. 40, no. 4, pp. 285–292, 1997.
View at: Google Scholar
S. Sultana, M. R. Khan, M. Kumar, S. Kumar, and M. Ali, “Nanoparticles-mediated drug delivery approaches for cancer targeting: a review,” Journal of drug targeting, 2012.
View at: Google Scholar
P. I. Huang, W. L. Lo, J. Y. Cherng, Y. Chien, G. Y. Chiou, and S. H. Chiou, “Non-viral delivery of RNA interference targeting cancer cells in cancer gene therapy,” Current gene therapy, vol. 12, no. 4, pp. 275–284, 2012.
View at: Google Scholar
M. Gupta, G. P. Agrawal, and S. P. Vyas, “Polymeric nanomedicines as promising vehicle for solid tumor therapy and targeting,” Current molecular medicine, 2012.
View at: Google Scholar
S. GuhaSarkar and R. Banerjee, “Intravesical drug delivery: Challenges, current status, opportunities and novel strategies,” Journal of controlled release: official journal of the Controlled Release Society, vol. 148, no. 2, pp. 147–159, 2010.
View at: Google Scholar
P. Tyagi, P. C. Wu, M. Chancellor, N. Yoshimura, and L. Huang, “Recent advances in intravesical drug/gene delivery,” Molecular pharmaceutics, vol. 3, no. 4, pp. 369–379, 2006.
View at: Google Scholar
S. A. Lewis, “Everything you wanted to know about the bladder epithelium but were afraid to ask,” American journal of physiology Renal physiology, vol. 278, no. 6, pp. F867–F874, 2000.
View at: Google Scholar
W. R. Richter and S. M. Moize, “Electron Microscopic Observations on the Collapsed and Distended Mammalian Urinary Bladder (Transitional Epithelium),” Journal of ultrastructure research, vol. 39, pp. 1–9, 1963.
View at: Google Scholar
B. F. Martin, “Cell replacement and differentiation in transitional epithelium: a histological and autoradiographic study of the guinea-pig bladder and ureter,” Journal of anatomy, vol. 112, Pt 3, pp. 433–455, 1972.
View at: Google Scholar
X. R. Wu, J. H. Lin, T. Walz et al., “Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins,” The Journal of biological chemistry, vol. 269, no. 18, pp. 13716–13724, 1994.
View at: Google Scholar
R. M. Hicks, “The mammalian urinary bladder: an accommodating organ,” Biological reviews of the Cambridge Philosophical Society, vol. 50, no. 2, pp. 215–246, 1975.
View at: Google Scholar
J. Yu, J. H. Lin, X. R. Wu, and T. T. Sun, “Uroplakins Ia and Ib, two major differentiation products of bladder epithelium, belong to a family of four transmembrane domain (4TM) proteins,” The Journal of cell biology, vol. 125, no. 1, pp. 171–182, 1994.
View at: Google Scholar
X. T. Kong, F. M. Deng, P. Hu et al., “Roles of uroplakins in plaque formation, umbrella cell enlargement, and urinary tract diseases,” The Journal of cell biology, vol. 167, no. 6, pp. 1195–1204, 2004.
View at: Google Scholar
M. M. Poggi, P. A. Johnstone, and R. J. Conner, “Glycosaminoglycan content of human bladders. a method of analysis using cold-cup biopsies,” Urologic oncology, vol. 5, no. 5, pp. 234–237, 2000.
View at: Google Scholar
D. Baris, M. R. Karagas, C. Verrill et al., “A case-control study of smoking and bladder cancer risk: emergent patterns over time,” J Natl Cancer Inst., vol. 101, no. 22, pp. 1553–1561, 2009.
View at: Google Scholar
M. P. Zeegers, F. E. Tan, E. Dorant, and P. A. van Den Brandt, “The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies,” Cancer, vol. 89, no. 3, pp. 630–639, 2000.
View at: Google Scholar
T. M. Morgan, K. A. Keegan, and P. E. Clark, “Bladder cancer,” Curr Opin Oncol., vol. 23, no. 3, pp. 275–282, 2011.
View at: Google Scholar
R. C. Reulen, E. Kellen, F. Buntinx, M. Brinkman, and M. P. Zeegers, “A meta-analysis on the association between bladder cancer and occupation,” Scand J Urol Nephrol Suppl., no. 218, pp. 64–78, 2008.
View at: Google Scholar
J. C. Balbi, M. T. Larrinaga, E. De Stefani et al., “Foods and risk of bladder cancer: a case-control study in Uruguay,” Eur J Cancer Prev., vol. 10, no. 5, pp. 453–458, 2001.
View at: Google Scholar
J. J. Bade, M. Laseur, A. Nieuwenburg, L. T. van der Weele, and H. J. Mensink, “A placebo-controlled study of intravesical pentosanpolysulphate for the treatment of interstitial cystitis,” British journal of urology, vol. 79, no. 2, pp. 168–171, 1997.
View at: Google Scholar
G. A. Barbalias, E. N. Liatsikos, A. Athanasopoulos, and G. Nikiforidis, “Interstitial cystitis: bladder training with intravesical oxybutynin,” The Journal of urology, vol. 163, no. 6, pp. 1818–1822, 1818.
View at: Google Scholar
J. C. Nickel, “Interstitial cystitis: a chronic pelvic pain syndrome,” The Medical clinics of North America, vol. 88, no. 2, pp. 467–481, xii, 2004.
View at: Google Scholar
J. W. Warren, J. Brown, J. K. Tracy, P. Langenberg, U. Wesselmann, and P. Greenberg, “Evidence-based criteria for pain of interstitial cystitis/painful bladder syndrome in women,” Urology, vol. 71, no. 3, pp. 444–448, 2008.
View at: Google Scholar
P. K. Matsuoka, J. M. Haddad, A. M. Pacetta, and E. C. Baracat, “Intravesical treatment of painful bladder syndrome: a systematic review and meta-analysis,” International urogynecology journal, 2012.
View at: Google Scholar
K. E. Andersson, “Treatment of the overactive bladder: possible central nervous system drug targets,” Urology, vol. 59, no. 5 Suppl 1, pp. 18–24, 2002.
View at: Google Scholar
L. Jasmin, G. Janni, H. J. Manz, and S. D. Rabkin, “Activation of CNS circuits producing a neurogenic cystitis: evidence for centrally induced peripheral inflammation,” The Journal of neuroscience: the official journal of the Society for Neuroscience, vol. 18, no. 23, pp. 10016–10029, 1998.
View at: Google Scholar
J. E. Marchand, G. R. Sant, and R. M. Kream, “Increased expression of substance P receptor-encoding mRNA in bladder biopsies from patients with interstitial cystitis,” British journal of urology, vol. 81, no. 2, pp. 224–228, 1998.
View at: Google Scholar
C. J. Fowler, “Bladder afferents and their role in the overactive bladder,” Urology, vol. 59, no. 5 Suppl 1, pp. 37–42, 2002.
View at: Google Scholar
A. J. Wein and P. M. Hanno, “Targets for therapy of the painful bladder,” Urology, vol. 59, no. 5 Suppl 1, pp. 68–73, 2002.
View at: Google Scholar
T. Y. Chen, J. Corcos, M. Camel, Y. Ponsot, and M. Tu le, “Prospective, randomized, double-blind study of safety and tolerability of intravesical resiniferatoxin (RTX) in interstitial cystitis (IC),” International urogynecology journal and pelvic floor dysfunction, vol. 16, no. 4, pp. 293–297, 2005.
View at: Google Scholar
M. B. Chancellor and N. Yoshimura, “Treatment of interstitial cystitis,” Urology, vol. 63, no. 3 Suppl 1, pp. 85–92, 2004.
View at: Google Scholar
A. Rosamilia, “Painful bladder syndrome/interstitial cystitis,” Best practice & research Clinical obstetrics & gynaecology, vol. 19, no. 6, pp. 843–859, 2005.
View at: Google Scholar
J. K. Parsons and C. L. Parsons, “The historical origins of interstitial cystitis,” The Journal of urology, vol. 171, no. 1, pp. 20–22, 2004.
View at: Google Scholar
M. C. Smaldone, Y. Vodovotz, V. Tyagi et al., “Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis,” Urology, vol. 73, no. 2, pp. 421–426, 2009.
View at: Google Scholar
P. Tyagi, V. Tyagi, N. Yoshimura et al., “Gender-based reciprocal expression of transforming growth factor-beta1 and the inducible nitric oxide synthase in a rat model of cyclophosphamide-induced cystitis,” J Inflamm (Lond)., vol. 6, 23, 2009.
View at: Google Scholar
A. D. Bangham, “A correlation between surface charge and coagulant action of phospholipids,” Nature, vol. 192, pp. 1197–1198, 1961.
View at: Google Scholar
J. W. Johnson, R. Nayar, J. J. Killion, A. C. von Eschenbach, and I. J. Fidler, “Binding of liposomes to human bladder tumor epithelial cell lines: implications for an intravesical drug delivery system for the treatment of bladder cancer,” Selective cancer therapeutics, vol. 5, no. 4, pp. 147–155, 1989.
View at: Google Scholar
X. R. Wu, “Urothelial tumorigenesis: a tale of divergent pathways,” Nature reviews Cancer, vol. 5, no. 9, pp. 713–725, 2005.
View at: Google Scholar
F. A. Barr, H. H. Sillje, and E. A. Nigg, “Polo-like kinases and the orchestration of cell division,” Nature reviews Molecular cell biology, vol. 5, no. 6, pp. 429–440, 2004.
View at: Google Scholar
U. Holtrich, G. Wolf, A. Brauninger et al., “Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 5, pp. 1736–1740, 1994.
View at: Google Scholar
G. Wolf, R. Elez, A. Doermer et al., “Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer,” Oncogene, vol. 14, no. 5, pp. 543–549, 1997.
View at: Google Scholar
R. Knecht, R. Elez, M. Oechler, C. Solbach, C. von Ilberg, and K. Strebhardt, “Prognostic significance of pololike kinase (PLK) expression in squamous cell carcinomas of the head and neck,” Cancer research, vol. 59, no. 12, pp. 2794–2797, 1999.
View at: Google Scholar
K. Strebhardt, L. Kneisel, C. Linhart, A. Bernd, and R. Kaufmann, “Prognostic value of pololike kinase expression in melanomas,” JAMA: the journal of the American Medical Association, vol. 283, no. 4, pp. 479–480, 2000.
View at: Google Scholar
M. Nogawa, T. Yuasa, S. Kimura et al., “Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer,” The Journal of clinical investigation, vol. 115, no. 4, pp. 978–985, 2005.
View at: Google Scholar
S. Seth, Y. Matsui, K. Fosnaugh et al., “RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer,” Molecular therapy: the journal of the American Society of Gene Therapy, vol. 19, no. 5, pp. 928–935, 2011.
View at: Google Scholar
C. J. Arum, Y. Kodama, N. Rolim et al., “A rat model of intravesical delivery of small interfering RNA for studying urinary carcinoma,” World journal of urology, vol. 28, no. 4, pp. 479–485, 2010.
View at: Google Scholar
J. J. Killion, D. Fan, C. D. Bucana, D. N. Frangos, J. E. Price, and I. J. Fidler, “Augmentation of antiproliferative activity of interferon alfa against human bladder tumor cell lines by encapsulation of interferon alfa within liposomes,” Journal of the National Cancer Institute, vol. 81, no. 18, pp. 1387–1392, 1989.
View at: Google Scholar
D. N. Frangos, J. J. Killion, D. Fan, R. Fishbeck, A. C. von Eschenbach, and I. J. Fidler, “The development of liposomes containing interferon alpha for the intravesical therapy of human superficial bladder cancer,” The Journal of urology, vol. 143, no. 6, pp. 1252–1256, 1990.
View at: Google Scholar
C. P. Dinney, S. Tanguay, C. D. Bucana, B. Y. Eve, and I. J. Fidler, “Intravesical liposomal muramyl tripeptide phosphatidylethanolamine treatment of human bladder carcinoma growing in nude mice,” Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research, vol. 15, no. 6, pp. 585–592, 1995.
View at: Google Scholar
J. Connor, R. Bannerji, S. Saito, W. Heston, W. Fair, and E. Gilboa, “Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells,” The Journal of experimental medicine, vol. 177, no. 4, pp. 1127–1134, 1993.
View at: Google Scholar
A. Porgador, B. Gansbacher, R. Bannerji et al., “Antimetastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells,” International journal of cancer Journal international du cancer, vol. 53, no. 3, pp. 471–477, 1993.
View at: Google Scholar
P. T. Golumbek, A. J. Lazenby, H. I. Levitsky et al., “Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4,” Science, vol. 254, no. 5032, pp. 713–716, 1991.
View at: Google Scholar
M. J. Brunda, L. Luistro, R. R. Warrier et al., “Antitumor and antimetastatic activity of interleukin 12 against murine tumors,” The Journal of experimental medicine, vol. 178, no. 4, pp. 1223–1230, 1993.
View at: Google Scholar
A. Porgador, R. Bannerji, Y. Watanabe, M. Feldman, E. Gilboa, and L. Eisenbach, “Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells,” J Immunol., vol. 150, no. 4, pp. 1458–1470, 1993.
View at: Google Scholar
G. Dranoff, E. Jaffee, A. Lazenby et al., “Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 8, pp. 3539–3543, 1993.
View at: Google Scholar
Y. Horiguchi, W. A. Larchian, R. Kaplinsky, W. R. Fair, and W. D. Heston, “Intravesical liposome-mediated interleukin-2 gene therapy in orthotopic murine bladder cancer model,” Gene therapy, vol. 7, no. 10, pp. 844–851, 2000.
View at: Google Scholar
G. J. Seymour, M. D. Walsh, M. F. Lavin, G. Strutton, and R. A. Gardiner, “Transferrin receptor expression by human bladder transitional cell carcinomas,” Urological research, vol. 15, no. 6, pp. 341–344, 1987.
View at: Google Scholar
A. S. Derycke, A. Kamuhabwa, A. Gijsens et al., “Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells,” Journal of the National Cancer Institute, vol. 96, no. 21, pp. 1620–1630, 2004.
View at: Google Scholar
M. O. Fraser, Y. C. Chuang, P. Tyagi et al., “Intravesical liposome administration—a novel treatment for hyperactive bladder in the rat,” Urology, vol. 61, no. 3, pp. 656–663, 2003.
View at: Google Scholar
P. Tyagi, M. Chancellor, N. Yoshimura, and L. Huang, “Activity of different phospholipids in attenuating hyperactivity in bladder irritation,” BJU international, vol. 101, no. 5, pp. 627–632, 2008.
View at: Google Scholar
Y. C. Chuang, P. Tyagi, C. C. Huang et al., “Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes,” The Journal of urology, vol. 182, no. 2, pp. 786–792, 2009.
View at: Google Scholar
Y. C. Chuang, P. Tyagi, H. Y. Huang et al., “Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis,” Neurourology and urodynamics, vol. 30, no. 3, pp. 421–427, 2011.
View at: Google Scholar
Y. C. Chuang, W. C. Lee, and P. H. Chiang, “Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome,” The Journal of urology, vol. 182, no. 4, pp. 1393–1400, 2009.
View at: Google Scholar
W. C. Lee, Y. C. Chuang, and P. H. Chiang, “Safety and dose flexibility clinical evaluation of intravesical liposome in patients with interstitial cystitis or painful bladder syndrome,” The Kaohsiung journal of medical sciences, vol. 27, no. 10, pp. 437–440, 2011.
View at: Google Scholar
C. Weber, C. Coester, J. Kreuter, and K. Langer, “. Desolvation process and surface characterisation of protein nanoparticles,” International journal of pharmaceutics, vol. 194, no. 1, pp. 91–102, 2000.
View at: Google Scholar
S. Bae, K. Ma, T. H. Kim et al., “Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types,” Biomaterials, vol. 33, no. 5, pp. 1536–1546, 2012.
View at: Google Scholar
B. Elsadek and F. Kratz, “Impact of albumin on drug delivery - New applications on the horizon,” Journal of controlled release: official journal of the Controlled Release Society, vol. 157, no. 1, pp. 4–28, 2012.
View at: Google Scholar
J. M. McKiernan, L. J. Barlow, M. A. Laudano, M. J. Mann, D. P. Petrylak, and M. C. Benson, “A phase I trial of intravesical nanoparticle albumin-bound paclitaxel in the treatment of bacillus Calmette-Guerin refractory nonmuscle invasive bladder cancer,” The Journal of urology, vol. 186, no. 2, pp. 448–451, 2011.
View at: Google Scholar
Z. Lu, T. K. Yeh, M. Tsai, J. L. Au, and M. G. Wientjes, “Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy,” Clinical cancer research: an official journal of the American Association for Cancer Research, vol. 10, no. 22, pp. 7677–7684, 2004.
View at: Google Scholar
J. M. Morachis, E. A. Mahmoud, and A. Almutairi, “Physical and Chemical Strategies for Therapeutic Delivery by Using Polymeric Nanoparticles,” Pharmacological reviews, 2012.
View at: Google Scholar
A. Kumari, S. K. Yadav, and S. C. Yadav, “Biodegradable polymeric nanoparticles based drug delivery systems,” Colloids and surfaces B, Biointerfaces, vol. 75, no. 1, pp. 1–18, 2010.
View at: Google Scholar
A. Di Martino, M. Sittinger, and M. V. Risbud, “Chitosan: a versatile biopolymer for orthopaedic tissue-engineering,” Biomaterials, vol. 26, no. 30, pp. 5983–5990, 2005.
View at: Google Scholar
M. N. Kumar, R. A. Muzzarelli, C. Muzzarelli, H. Sashiwa, and A. J. Domb, “Chitosan chemistry and pharmaceutical perspectives,” Chemical reviews, vol. 104, no. 12, pp. 6017–6084, 2004.
View at: Google Scholar
R. C. Read, S. C. Naylor, C. W. Potter et al., “Effective nasal influenza vaccine delivery using chitosan,” Vaccine, vol. 23, no. 35, pp. 4367–4374, 2005.
View at: Google Scholar
E. A. McNeela, I. Jabbal-Gill, L. Illum et al., “Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan,” Vaccine, vol. 22, no. 8, pp. 909–914, 2004.
View at: Google Scholar
D. A. Zaharoff, B. S. Hoffman, H. B. Hooper et al., “Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12,” Cancer research, vol. 69, no. 15, pp. 6192–6199, 2009.
View at: Google Scholar
V. Dodane, M. Amin Khan, and J. R. Merwin, “Effect of chitosan on epithelial permeability and structure,” International journal of pharmaceutics, vol. 182, no. 1, pp. 21–32, 1999.
View at: Google Scholar
B. Ghosn, A. L. van de Ven, J. Tam et al., “Efficient mucosal delivery of optical contrast agents using imidazole-modified chitosan,” Journal of biomedical optics, vol. 15, no. 1, 015003, 2010.
View at: Google Scholar
E. Bilensoy, C. Sarisozen, G. Esendagli et al., “Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of Mitomycin C to bladder tumors,” International journal of pharmaceutics, vol. 371, no. 1-2, pp. 170–176, 2009.
View at: Google Scholar
S. A. Wissing, O. Kayser, and R. H. Muller, “Solid lipid nanoparticles for parenteral drug delivery,” Advanced drug delivery reviews, vol. 56, no. 9, pp. 1257–1272, 2004.
View at: Google Scholar
J. X. Wang, X. Sun, and Z. R. Zhang, “Enhanced brain targeting by synthesis of 3',5'-dioctanoyl-5-fluoro-2'-deoxyuridine and incorporation into solid lipid nanoparticles,” European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV, vol. 54, no. 3, pp. 285–290, 2002.
View at: Google Scholar
H. L. Wong, R. Bendayan, A. M. Rauth, and X. Y. Wu, “Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers,” Journal of pharmaceutical sciences, vol. 93, no. 8, pp. 1993–2008, 2004.
View at: Google Scholar
Y. Li, N. Taulier, A. M. Rauth, and X. Y. Wu, “Screening of lipid carriers and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles (PLN),” Pharmaceutical research, vol. 23, no. 8, pp. 1877–1887, 2006.
View at: Google Scholar
R. K. Subedi, K. W. Kang, and H. K. Choi, “Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin,” European journal of pharmaceutical sciences: official journal of the European Federation for Pharmaceutical Sciences, vol. 37, no. 3-4, pp. 508–513, 2009.
View at: Google Scholar
Z. Xu, L. Chen, W. Gu et al., “The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma,” Biomaterials, vol. 30, no. 2, pp. 226–232, 2009.
View at: Google Scholar
X. Lin, R. Gao, Y. Zhang et al., “Lipid nanoparticles for chemotherapeutic applications: strategies to improve anticancer efficacy,” Expert opinion on drug delivery, 2012.
View at: Google Scholar
R. H. Muller, M. Radtke, and S. A. Wissing, “Nanostructured lipid matrices for improved microencapsulation of drugs,” International journal of pharmaceutics, vol. 242, no. 1-2, pp. 121–128, 2002.
View at: Google Scholar
M. R. Kang, G. Yang, R. F. Place et al., “Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth,” Cancer research, 2012.
View at: Google Scholar
P. Ekambaram and H. S. Abdul, “Formulation and evaluation of solid lipid nanoparticles of ramipril,” Journal of young pharmacists: JYP, vol. 3, no. 3, pp. 216–220, 2011.
View at: Google Scholar
J. Klostergaard and C. E. Seeney, “Magnetic nanovectors for drug delivery,” Nanomedicine: nanotechnology, biology, and medicine, 2012.
View at: Google Scholar
L. Gommersall, I. S. Shergill, H. U. Ahmed et al., “Nanotechnology and its relevance to the urologist,” European urology, vol. 52, no. 2, pp. 368–375, 2007.
View at: Google Scholar
B. Chertok, B. A. Moffat, A. E. David et al., “Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors,” Biomaterials, vol. 29, no. 4, pp. 487–496, 2008.
View at: Google Scholar
C. H. Chen, H. J. Yang, C. T. Shun et al., “A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer,” Urologic oncology, 2010.
View at: Google Scholar
S. C. Goodwin, C. A. Bittner, C. L. Peterson, and G. Wong, “Single-dose toxicity study of hepatic intra-arterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier,” Toxicological sciences: an official journal of the Society of Toxicology, vol. 60, no. 1, pp. 177–183, 2001.
View at: Google Scholar
T. Leakakos, C. Ji, G. Lawson, C. Peterson, and S. Goodwin, “Intravesical administration of doxorubicin to swine bladder using magnetically targeted carriers,” Cancer chemotherapy and pharmacology, vol. 51, no. 6, pp. 445–450, 2003.
View at: Google Scholar
Z. Shen, T. Shen, M. G. Wientjes, M. A. O'Donnell, and J. L. Au, “Intravesical treatments of bladder cancer: review,” Pharmaceutical research, vol. 25, no. 7, pp. 1500–1510, 2008.
View at: Google Scholar
T. C. Zuiverloon, A. J. Nieuweboer, H. Vekony, W. J. Kirkels, C. H. Bangma, and E. C. Zwarthoff, “Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review,” European urology, vol. 61, no. 1, pp. 128–145, 2012.
View at: Google Scholar

Copyright

Copyright © 2012 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation Order printed copies

Views

1104

Downloads

936

Citations